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ABSTRACT
Studies of limb regeneration have implicated the nervous system
in promoting osteogenesis. The neurotrophic hypothesis states that
neurons synthesize a substance, called a neurotrophic factor, which
is transported to distant tar.get organs or tissues.
Tn_ objective of this study was to investigate the direct
neural involvement in osteogenesis. This study utilized in vitro
cell culture techniques, focusing on two known neurotrophic
substances, nerve growth factor (NGF) and vasoactive intestinal
peptide (V.IP). The effect of these agents on the growth or’
phenotypio expression of the permanent, clonal osteoblastic cell
line, Rat Osteosarcoma (ROS 17/2.8) cells was assessed. Growth of
the ROS 17/2.8 cells was determined by the cell number (measured by
the coulter counter) and the osteoblastic differentiation was
determined by the specific biochemical assay of alkaline phosphatase
(AP, a specific osteoblastic marker). The ROS 17/2.8 cells were
pre-incubated for 2 days in a culture medium consisting of modified
Ham’s F-12, I% kanamycin sulfate and 5% fetal bovine serum (FBS).
During the experimental period the cells were maintained with Ham’s
F-12, 2% FBS, I% kanamycin and the test agent. The hypothesis was
that the addition of VIP and NGF alters the AP specific activity (Sp
Ac) or cell number of the ROS 17/2.8 cells.
NGF and VIP had the following direct effects on osteoblastic
growth and differentiation"
I VIP increased the Ap Sp Ac and cell number, when measured
sixty hours following the initial addition of five doses of
0.165 ug/ml at 12 hour intervals. This condition decreased
the protein content. VIP had a similar effect when added
in a single dose of 0.825 ug/ml.
2. VIP increased the AP Sp Ao and cell number, and decreased
the protein content when measured seventy hours following
the addition of a single dose (0.50 ug/ml and 1.0 ug/ml).
5. NGF inhibited the AP Sp Ac and increased the cell number
and protein content when measured sixty hours following the
addition of a single dose (0.025 ug/ml).
The phosphodiesterase inhibitor, isobutylmethylxanthine
(IBMX), either alone o in combination with otheF agents
decreased AP Sp
5. The effect of VIP in increasing AP Sp Ac was more
pronounced in the presence of IBMX and NGF.
These results are consistent with the hypothesis that the
osteobl-ast responds directly to the neurotrophic substances VIP and
NGF.
INTRODUCTION
The objective of this reseaFch was to investigate whether
vasoactive intestinal peptide (VIP) and nerve growth factor (NGF)
act as direct regulators of skeletal cell physiology. To est this
hypothesis, the effects of VIP and NGF on the differentiation or
proliferation of rat osteosarcoma (ROS) 1’7/2.8 permanent, clonal
osteoblastio cell line were examined.
Nerves regulate the growth, maintenance and repair of target
organs or tissues, probably via specific chemical substances (Dubner
et al., 1978). This relationship, in which nerve cells and target
cells interact so as to influence the structure or function of
either member, is called neurotrophism (Drachman, 1974).
The neurotrophic hypothesis (Singer, 1978) states, neurons
synthesize a substance, called a neurotrophic factor which is
transported to distant target organs or tissues. Much of the
evidence for neurotrophism comes from regeneration studies.
Regeneration of an amputated limb, has been reported in the
newt (Singer, 1952), rats (Becket, 1972; Libbin et al., 1979), mice
(Neufeld, 1980) and children (Douglas, 1972; Illingworth, 1974;
Rosenthal et al., 1979).
Singer (1952) postulated that the role of nerves in
regeneration is mediated by a chemical trophic factor. Both sensory
and motor fibers are able to maintain limb regeneration although a
larger number of motor fibers appear to be necessary (Singer, 1946,
1952). The intensity of regeneration is determined by the number of
nerve fibers present (Guth, 1969). When nerves grow into an
amputated aneurogenic stump, regeneration is accelerated (Yntema,
1959). When the nerves are resected after partial regeneration has
occured, further growth is prevented and the partial regenerate may
regress to the original amputation site (Singer and Craven, 1948).
Thus, the ner.vous system has been implicated in osteogenesis, bone
formation and resorption. Since regeneration studies involve the
total system there is the complication of tissue interactions.
Therefore, a direct connection between limb regeneration and bone
growth is not proven in regeneration studies. Utilizaton of the
cell culture technique would be helpful when investigating a direct
effect.
There have been conflicting reports of possible neural
involvement in skeletal physiology. Some of the studies indicating
that the neural involvement is not important in skeletal physiology
include the findings of Corbin and Hinsey (1939), that the skeleton
can be maintained even when completely denervated (1-3 sacral dorsal
and lumbar sympathectomy in cats). Also, some investigators did not
find any changes in long bone growth in thoracolumbar
sympathectomized cats (Harris and McDonald, 1936; Cannon et al.,
1929), rats (Bacq, 1936), goats (Bisgard, 1938), dogs or lambs
(Harris and McDonald, 1936). However, Harris and McDonald (1936)
stated that muscular activity was essential to normal growth and
that sympathectomy would not produce visible changes in leg length
in cases of extensive paralysis. Ashton (1980) reported
osteogenesis occured in mil lipore filter chambers in the total
absence of neural celis. However, the "in vivo" environment, seemed
essential for this process.
Denervation studies should be interpreted carefully since such
experiments result in muscular, circulatory, neuronal and disuse
effects. During surgical denervation, there is the complicating
factor of muscle damage, which is important when inteFpreting the
Fesults. Also, in Fegional migratory osteoporosis, which is
transient localized demineralization, the muscles overlying the
affected area are denervated. Thus, this in vitro study of the
neuFal involvement via NGF and/or VIP is an alternate approach to
this question regarding skeletal physiology.
The first neurotrophic substance to be identified was NGF
(Bueker, 1948). NGF has been pFoposed as a possible agent
regulating trophic interactions in the peripheral nervous system
(Varon and Bunge, 1978). Greene and Shooter (1980) suggest a
possible extraneuronal role for NGF. Specific binding sites for NGF
have been found in the brain, adrenal gland, heart, abdominal aorta,
liver, spleen, uterus, kidney, diaphragm and skeletal muscle
(Frazier et al., 1974).
A possible role for NGF in bone remodeling was reported by
Teitelbaum et al. (1978). The effects of NGF on maintaining cranial
bone and cartilage as differentiated neural crest cells were
discussed by Coulombre et al. (1974).
Weis and Weis (1970) found an increase in the length of
regenerating limbs and in the rate of digit formation in Ambystoma
following administration of NGF.
Saide et al. (1975) observed that patients with Paget’s disease
(intense bone remodeling and rapid proliferation of fibroblasts)
have higher serum concentrations of NGF.
VIP is a single chain peptide of 28 amino acids, mol. wt.
33OO. VIP was first isolated from porcine small intestine (Said
and Mutt, 1970) and has since been localized within neurons by
radioimmunological and immunohistochemical methods (Fuxe et al.,
VIP is synthesized as part of the po lyprotein, pre-proVIP.
Tsukada et al. (1985) have isolated and determined the structure of
the human vasoactive intestinal po lypeptide gene. Marie et al.
(1985) found that the tyrosyl residue (Tyr-22) and the localized
hydrophobio features of VIP are critically involved in the function
of V IP. In the periphery, post-ganglionic parasympathetic neurons
containing VIP innervate blood vessels and secretory epithelial
cells where electrical stimulation results in an increase in VIP,
which causes vasodilation and secretion in salivary glands
(Fahrenkrug, 1979; Uddman et al., 1980). Scott and Baum (1985)
reported that cAMP and calcium were involved in the exocrine protein
secretion induced by VIP in rat parotid cells. VIP also
synergistically stimulated parotid secretion when combined with
substance P, another neurotransmitter and a sialogogue (Ekstrom and
Olgart, 1986).
VIP is a putative neurotransmitter in the system referred to as
the peptidergic nervous system (Sundler et al., 1980) or the so
called VIPergic system (Polak and Bloom, 1982). Under conditions of
electrical blockade, Brenneman and Eiden (1986) demonstrated the
neurotrophic action of VIP on neuronal survival. VIP has a large
spectrum of important biologic activities including it’s effect on
blood flow, smooth muscle relaxation, exocrine secretion and
endocrine, neuroendocrine activity.
For certain agents (PTH, PGE) the irst step in the stimulation
of bone resorption is probably binding of the hormone to specific
cell surface receptors, followed by the activation of adenylate
cyolase and increases in cAMP. Hohmann and coworkers (1983) found
that VIP causes a dose-dependent increase in bone resorption via a
cAMP-dependent, prostaglandin (PG) independent mechanism. It has
been suggested that most agents that increase cAMP levels in bone do
so via the osteoblast, which then act to stimulate and/or recruit
the osteoclast, resulting in bone resorption (Rodan and Martin,
1981). Hohmann and Tashjian (1984) found that human osteosarcoma
cells respond to VIP with an increased production of cAMP which is
mediated by speciio surface receptors for VIP. McSheehy and
Chambers (1986) report that osteoblastic cells mediate osteoclastic
responsiveness to PTH, which is also consistent with Rodan and
Martin’s (1981) hypothesis.
Some clinical findings of relevance are- I.) The report of a
case of VlP-secreting ganglioneuroma with the predominant clinical
picture of growth failure with intermittent secretory diarrhea and
soiling. The short stature with severe growth failure was a
dominant feature in the absence of weight loss, malabsorptin or ill
health (Granot et al., 1983). 2.) Kaplan and coworkers (1980)
reported earlier on a VIP secreting tumor of childhood which
included in the clinical picture, failure to thrive, with the
child’s height and weight below the third percentile.
Laburthe et al. (1986) reported that AC-Tyrl hGRF (human growth
hormone-releasing factor with position I substituted .Ac-Tyrl analog)
is a competitive VIP antagonist in the rat. N-terminal histidine
(position I, Hisl) is important for peptide interaction with VIP
receptors. Chihara and coworkers (1984) report the stimulation of
growth hormone by VIP in acomegaly. Previous studies found that
VIP stimulates GH secFetion fom GH-seceting pituitary adenoma i__qn
vitro (Chihara et al., 1982; Matsushita et al., 1981). Again, these
conflicting reports, on the possible involvement of the nervous
system indicate the complexity of the total system. Therefore,
utilization of cell culturing may provide useful information
regarding a direct effect.
The rat osteosarcoma clonal cell lines (ROS) were selected on
the basis of parathyroid hormone-sensitive adenylate cyolase. These
cells express the following osteoblastic characteristics: elevated
AP, I,29-(0H)2 vitamin D3 receptors, bone -carboxyglutamic acid
protein synthesis stimulated by 1,25-(0H) 2 vitamin D3, osteogenesis
in subcutaneous tumors and implanted Millipore filter chambers
(Majeska et al., 1980). In R0S 17/2.8 cells, proliferation and
phenotypic expression (exemplified by cell number’ and AP activity)
is modulated by hormones known to affect bone (e.g. PTH). Even
though differentiation is coupled to growth aFrest, the arFest of
gFowth does not necessarily result in differentiation.
Therefore, the goal of this study is to provide insight into
possible direct effects of the nervous system on osteoblasts.
Specifically, the effect of VlP and NGF on growth and
differentiation was investigated.
ObOeqt.ive and Hypqthgsis
The obOeotive of this study is to investigate the neural
involvement in osteogenesis. As discussed under the Introduction
section, neurotrophism has been investigated mostly via regeneration
studies of the limb. These in vivo studies are difficult to
interpFet because of the muscular, circulatory, neuronal and disuse
effects. This study utilized in vitro culture techniques;
focusing on two known neurotrophio substances, NGF and VIP. The
effect of these agents on growth or phenotypic expression of the
permanent, clonal, osteoblastic cell line, Rat Osteosarcoma (ROS
17/2.8) were assessed by determining the cell number and by the
specific biochemical assay of alkaline phosphatase (AP). Alkaline
phosphatase is a specific osteoblastic marker, used to determine
osteoblast differentiation.
In summary, the objective was to determine if VIP and NGF
effect the differentiation or pro liferation of ROS 1 7/2.8 ce I I s.
The hypothesis is that the addition of VIP and NGF alters the AP
specific activity or cell number of ROS 17/2.8 cells.
MATERIALS AND METHODS
Materials
Cell culture medium, serum and antibiotics were purchased from
GIBCO, Grand Island, NY. Culture plastioware was from COSTAR,
Cambridge, MA. Hepes, 2-amino-2-methyl-l-propanol, disodi.um p-
nitrophenylphosphate, p-nitrophenol, vasoactive intestinal peptide
(VIP), Tris (hydroxymethyl)-aminomethane and bovine serum albumin
(BSA) were from Sigma, St. Louis, MO. Triton X-tO0 was from Rohm
and Haas, Philadelphia, PA. Isobutylmethylxanthine (IBMX) was from
Aldrich Chemical Co., Milwaukee, WI. 7S-Nerve Growth Factor was from
Collaborative Research, Inc., Lexington, MA.
Populati_on to b__e Stdied
The permanent, clonal osteoblastic cell line, Rat Osteosarcoma
(ROS 17/2.8) cells was utilized to facilitate the study of
osteoblastic cells in culture. Cell culture minimizes differences
between experiments due to heterogeneity and the loss of phenotypic
properties, which are present in organ culture and primary cell
cultures.
Cell Culture and Maintenance
The maintenance medium consisted of modified Ham’s F-12
(Majeska and Rodan, 1982a) containing I% kanamycin sulfate and
supplemented with either 10% or 5% fetal bovine serum (FBS).
Cultures were kept at 37C in a humidified 95% air/5 CO2
atmosphere, and were subcultured weekly.
I0
Ce l____!l .C0un.t ing
FoF expeFiments, cell suspensions were prepared at the
appropriate density for each expeFiment, and ml portions were
plated in 24 multiwell plates.
The following proceduFes were performed, to plate out 20,000
cells/well [in a 16 mm diameter well (P-16) which has a culture area
of 2 cm2 and a medium volume of I ml]. First, the medium was
aspirated from a P-tO0 (100 mm diameter culture dish) of confluent
ROS ce i i s. Next, 2.0 ml of 0.01% trypsin was added for 5 minutes,
then the trypsin was removed. Next, 0.5 ml of 0.01% trypsin was
added to the culture plates which were placed in the incubator at
57C for 8-I0 minutes. This was followed by re suspension of the
cells in 10 ml of medium (5%FBS, I% kanamycin). Then the cell
suspension was pipetted into a 16 ml tube; the cells were thoroughly
mixed by pipe tting up and down. With the same pipette, 0.5 ml was
removed aseptically and added to 9.5 ml saline (0.9 NaC1) in a
cuvette. Each sample was counted three times.
The number of cells per milliliter in the test tube was
determined by the average count, which is multiplied by .40 because
of the following calculation"
Average count (# of cells) x 10 ml total volume/0.5 ml sample size x
/0.5 -ml coulter counting volume
Average count(number of cells) x 0 number oZ oells/ml
The seeding density of 20,000 cells/well, which is equivalent to
10,000 oells/cm2 was prepared utilizing the determined number of
cells/ml. Since each well contains a medium volume of I ml, the
appropriate number of cells were removed from the test tube and
placed in a sterile bottle with the correct amoun of medium.
For example, if the average cell count was 19,754 cells x 40
790,147 cel is/ml. In experiment #I, 100 welis required 20,000
cells/well necessitates 2,000,000 cells/lO0 wells. Since there were
790,147 cel ls/ml a 2.53 ml aliquot was removed and placed in 97.47
ml medium (%5 FBS, I% kanamycin). Then I ml of this mixture was
added to each of the 100 wells. The preincubation period was 2
days.
At the end of each experiment, the following procedure was used
count the number of celis per 16mm well: The medium was fir st
aspirated from each well and the cells were rinsed once with CMFH.
Then 0.5 ml of 0.01% trypsin was added to each well and the plate
was incubated at 37C Zor 8-10 minutes. Next, 0.5 ml saline (0.9%
NaCL) was added to each well; the cells were resuspended and
pipetted into pre-loaded cuvettes containing 9.0 ml saline. Each
sample was counted three times. This average count was for the 0.5
ml aliquots of the 10 ml in each cuvette. Therefore, each average
value of the cell counts was multiplied by a factor of 20, in order
to obtain the actual number of cells/well.
.A!kal_ne Phospha_t_ase Assa_____
First, the medium was aspirated from the wells; then each well
was rinsed once with CMFH, followed by the addition oZ 0.5 ml oZ the
sample buZZer (lOmM Tris-HCl, pH 7.5, 0.5 mM MgCI2, 0.1% triton X-
I00) to each well. Next, the wells were scraped with a plastic
scraper and the sample were pipetted into plastic test tubes and
either kept on ice or frozen until assayed.
Ten microliter aliquots of the sample were placed in duplicate
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test tubes and kept on ice. At time O, 0.180 ml of the alkaline
phosphatase assay mixture containing 0.I M 2-amino-2-methyl-1-
propanol, 2mM MgC12, 2 mM Na2 p-nitrophenylphosphate (Na2PNPP) was
added, followed by vortexing and incubation in a 37C water bath.
The reactions were stopped with 0.8 ml of 1.0 N NaOH and the
absorbance was read at 410 nm. When using ROS 17/2.8 the reaction
is linear for about 20 min with up to 3 ug of protein.
rotein_ eteminatio_n_ b_z Coomassi_e Blu___e G_ (_Spector,1978)-
Duplicate assay tubes were prepared containing 10 ul aliquots
of each sample. To each assay tube 100 ul o.f H20 was added. A
protein standard curve was prepared usi.ng the 500 ug/ml stock
solution of BSA as foliows: The BSA stock solution was diluted 1:10
(100 ul of BSA + 900 ul of H20). A series of tubes (duplicates)
were pepared containing O, I, 2, 5, or 5 ug of BSA. This is
equivalent to O, 20, 40, 60, 80 or 100 ul of the diluted stock BS.A.
Each standard is brought up to a volume of 100 ul with H20. Then,
to each standard tube 10 ul of sample buffer (10 mM Tris-HCl pH 7.5,
0.5 mM MgCI 2, 0.1% Triton X-tO0)was added. To all test tubes
(samples and standards) 900 ul of the Coomassie Blue G reagenc was
added. The test tubes were allowed to stand at room temperature for
5 min. Then the absorbance was read in the spectrophotometer at 595
nm. Protein concentrations were determined using standard curves
obtained by linear regression analysis.
Spec_ifi c Ac.t. ivit._.y__ of Al_kali_ne Phosphatase Detrmination
The specific activity (Sp Ac) of alkaline phosphatase (AP) was
determined using the following equation:
Sp Ac (umole/min/mg protein) (Xab41 0 Blankab410) x
O.0574/Tmin/Protein rag; where T "5 minutes in experiment and # 5
and T 4 minutes in experiment #2, X mean absorbance st 410 nm,
Blank absorbanoe at 410 nm of 180 ul Buffer + 800 ul NaOH, 0.0574
is derived from the molar extinction coefficient of p-nitophenol,
the reaction product. Values for Sp Ac were calculated for each
well, the means and standard deviations were determined for each
group using these values.
p.r=_e_=par_ation of Substances:
Vasoactive intestinal peptide (0.25 mg VIP) was dissolved in
1.0 ml of 0.I HAC, 0.1g BSA, pH 4.0. This was the stock VIP (250
ug VIP/ml HAC-BSA). The control (vehicle) for VIP was HAC-BSA.
NeFve growth factor (100 ug NGF) was dissolved in 1.0 ml medium
(2 FBS, I% kanamyoin). This was the stock NGF (I00 ug NGF/ml
medium). NO GLASS WAS USEDWITH NGF (plastic pipettes were used).
The control (carrier-vehicle) foF NGF was the culture medium (2
FBS, I% kanamyoin).
The stock 20 mM IBMX was prepared by dissolving 4.4 mg IBMX in
1.0 ml of 0.2 N NaOH. The control (carrier-vehicle) for IBMX was
0.2 N NaOH.
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Treatment of 17/2.8 Cultures with Vasoactive Inte.si_na_! P.9tide,_
Nerve Growt-- Factor a---d IB-----X------
Experiment # Design:
ROS 17/2.8 cells previously maintained in I0% FBS were seeded
into one 4 well (16 mm) and four 24 well (16 ram) plates at a density
of 0,000 cells/om2 (20,000 cells/well) in 5 FBS, I kanamyoin
medium. After 2 days, two-wells were assayed for cell number, and
two for alkaline phosphatase and protein. The remaining wells were
fed with medium containing 2% FBS and test agents as shown below.
In experiment #1a, one dose of 0.825 ug VlP/ml was added to two of
the 24 well plates. In experiment #1b, 5 doses of 0.165 ug VIP/ml,
at 12 hour intervals was added to the two remaining 24 well plates.
Sixty hours following the initial addition of the agents, alkaline
phosphatase., protein content and cell number were determined.
Figure I. Experiment #1 Design
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Experiment #2 Design
One 4 well (6mm) and two 24 well (6mm) plates were seeded at
30,000 cel is/16mm well. The cells were grown for 2 days in 2% FBS,
I% kanamycin medium, then fed with 0.2% FBS, I kanamycin medium
containing test agents shown below. Ninety-six hours following the
addition of the agent, alkaline phosphatase, protein content and
cell counts weFe determined.
Figure 2. Experiment #2 Design
C
0 0 0
ooo
0 0 0
V3
o 0o
2
0 0 0
0-0o
0 0 0
N NI+V3
C V4
---AP ’0 0 0 0 0-0
iCOUNT 0 0 0 0 0 0
AP-----+ 0 0 0 0 0 0
N2 N2+V4
C Control
carrier-
vehicle
V5 1.0 ug VlP/ml
V4 0.5 ug VlP/ml
N1 0.25 ug NGF/ml
N2 0.1 ug NGF/ml
t 0
Experiment #5 Design
Two 24 well (16ram) plates were seeded at a density of 20,000
cells/16mm well. The cells were grown for 2 days in 5% FBS, 1%
kanamycin medium, then fed with 2% FBS, 1% kanamycin medium
containing-the concentrations of VIP illustrated in Figure 3. Cell
counts, AP and protein measurements were performed 70 hours after
the addition of the test agents.
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Figure 5. Experiment #5 Design
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RESULTS
In this study, both of the neural factors, NGF and VIP had
direct effects on the ROS cells. In experiment #1a, the addition of
one dose of 0.825 ug VIP/ml produced small increases in AP specific
activity and cell number and a decrease in the protein content. In
comparison to untreated controls, by the T-test, these were small.
Similarly, NGF increased the cell number and protein content; and
inhibited AP activity.
The effect of IBMX was marked. When IBMX was compared to the
untreated control, using the T-test, there was a decrease in AP
specific activity and cell number, and a significant increase in
protein content. In Experiment #1(a+b), all of the values of AP Sp
Ac which were significantly decreased had IBMX added. IBMX is a
phosphodiesterase inhibitor, which inhibits the destruction of cAMP.
Binding of a hormone to a membrane receptor induces intracellular
cAMP. Cyclic AMP activates protein kinases which phosphorylate
intracellular proteins. Cyclic AMP is synthesized from ATP by the
plasma membrane bound enzyme, adenylate oyolase, and is rapidly
destroyed by phosphodiesterase.
While few of -these effects were significant when analyzed by
the T-test, the 5-way ANOVA showed a significant effect. The
Three-Way Analysis Of Variance (5-Way ANOVA) was performed on the
values in Table with the results shown in Table 2. When VIP was
added a significant difference was found in AP Sp Ac and protein
content. When NGF was added, a significant difference was found in
AP Sp .Ac. When IBMX was added, a significant difference was found
in AP Sp Ao, cell number and protein content. When VIP + IBMX was
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added, an interaction was found to affect the protein content. When
NGF + IBMX were added, an interaction was found to affect the AP Sp
Ac and protein content.
Then, in experiment #1b, when five doses of 0.165 ug VlP/ml was
added at 12 hour intervals, there was an increase in AP Sp Ac and
cell number and a decrease in protein content. Similarly, NGF
stimulated AP activity and cell number and inhibited .protein
content.
The 3-Way ANOVA was performed on the values from Table 3, with
the results shown in. Table 4. When VIP was added in five doses, at
12 hour intervals, a significant effect was found on AP Sp Ac, cell
number and protein content. The addition of NGF had a significant
affect on cell number. The addition of IBMX affected the AP Sp Ac
and cell number. An interaction was found with VIP + NGF on the AP
Sp Ac, cell number and protein content.
In experiment #2, within one plate, using the T-test to compare
0.25 ug NGF/ml to the untreated control, there was a significant
increase in cell number, and on the other plate, the addition of 0.1
ug NGF/ml produced a significant decrease in AP Sp Ac. However, the
variation between controls on the two plates was so large that is
was not possible to deduce effects of VIP and NGF.
Experiment #3 was designed to replicate the experimental
conditions in experiment #1a, with respect to plating density, and
the length of the treatment period. In this experiment, with a
larger sample size, the effects were small and not statistically
significant, although the direction was the same as experiment #I.
Also, at the highest concentration (1.5 ug VlP/ml) tested, a
reversal of this effect was observed.
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Table 1. Experiment #1a, Number of CelIs/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following
Addition of Agents to ROS 17/2.8 Cells
[VIP] [NGF] [IBMX] Cell Number/Well AP Sp Ac
ug/ml ug/ml mM x I0 mg protein umol/min/mg
0 0 0 6.464 / 1.235 .0770 + .0104 .613 + .1264
825 0 0 6. 779 + 0.965 .0690 + .0017 .727 + .1228
825 0 .2 4. 877 + 0.922 .0758 + .0023 .323 + .0214"
.82 .025 .2 6.076 + 0.730 .0735 + .0221 .362 + .0839*
.825 .025 0 6.264 + 1.476 .0813 + .0023 .552 + .0643
0 .025 0 7.346 + 0.656 .0990 + .0035* .462 + .0523
0 .025 .2 6. 398 + 0.361 .1093 + .0014" .236 + .0182"
0 0 .2 5. 728 + 0.266 .1195 + .0095" .228 + .0047"
All values are the mean +SD.
The test agents were added for 60 hours in 2% serum.
*Significant difference at P<.05 when compared to untreated contro I s.
Table 2. Experiment #1a,
Table 1
Analysis Of Variance For Values From
Factor
F Value For Effect On
AP Sp Ac Cel I Number Protein Content
VIP 11.849"* 1. 501 46. 450**
NGF 5.097* 2.004 2.151
IBMX 95.060** 5. 685* 11 61 3**
VIPxNGF 0.003 0.303 0.0116
VIPx IBMX O. 018 0. 067 1 2. 058**
NGFxIBMX 9.115"* 0.899 9.512"*
VIPxNGFxIBMX O. 189 1 490 1.258
Significant effect of factor or factors (axb) on AP Sp Ac,
Number and/or Protein Content at** P< .01 *P <.05
Cell
2O
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Table 3.
[VIP]
ug/ml
Experiment #1b, Number of Celis/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following Addition
of Agents to ROS 17/2.8 Cells
[ NGF] [ IBMX ] Ce I i Oumber/We i i AP Sp Acug/ml mM xl mg Protein umol/min/mg
.165x5 0 0 7.311 + 0.180" .0662 + .0104" .722 + .1422"
165x5 0 .2 6.424 + 0.299* .0703 + .0161" .459 + .1474
165x5 .025 .2 5. 384 + 1.484 .09’77 + .0271 .283 + .0890"
165x5 .025 0 8.645 + 1.371" .0795 + .0188" .617 + .1154"
0 .025 0 6.947 + 1.077" .0852 + .0037* .541 + .0885*
0 .025 .2 5.659 + 0.677 .0957 + .0054* .299 + .0243*
0 0 .2 3.111 + 0’931 .1140 + .0162 .243 + .0340*
0 0 0 4.523 + 1.345 .1075 + .0028 397 + .0588
All values are the mean +SD
above initial test agents were added for 60 hours in 2% serum.
Significant difference at P<.05 when compared to untreated controls.
Table 4. Experiment #1b,
Table 3
Analysis of Variance For Values From
Factor
F Value For Effect On
AP Sp Ac Cell Number Protein Content
VIP 12.814"* 22. 361"* 11.821"*
NGF 0.235 10.956"* 0,000
IBMX 35. 061 ** 18..527** 2,326
VlPxNGF 8.21 5** 8. 646** 9. 947**
VIPxlBMX I 438 O. 829 0.0428
NGFxIBMX O. 91 6 2 000 O. 487
VIPxNGFx IBMX 0.011 2.464 0.150
Significant effect of factor or factors (axb) on AP Sp Ac,
Number and/or Protein Content at **PK .01 *P < .05
Cell
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Table . Experiment #2, Number of Cells/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following
Addition of VIP and NGF to ROS 17/2.8 Cells
[VIP] [NGF] Cell Nmber/Well AP Sp Ac
ug/ml ug/ml x10 mg Protein umol/m_.n/mg
0 0 10.110 + 2.417 .037 + .0113 2.298 + .4152
1.0 0 14.226 + 2.826 .043 + .0047 2.144 + .3629
0 .25 14. 171 + 1.836" .043 + .0078 2. 163 + .4]583
1.0 .25 14.351 + 2.642 .044 + .0120 2.095 + .5401
0 0 14.455 + 1.874 .043 + .0168 2.863 +1.4490
5 0 16.039 + 1.211 .047 + .0184 2.300 + .8287
0 .1 13.905 + 2.789 .053 + .0100 1.716 + .3012"
5 .1 16.166 + 3.283 .053 + .0245 2.479 +1.1844
All values are the mean +SD.
The above test agents were added for 96 hours in 0.2% serum medium.
*Significant difference at P<.05 when compared to the untreated
controls.
Table 6. Experiment #3, Number of Cells/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following Addition
o VIP to ROS 17/2.8 Ceils
[VIP]
ug/ml
Cell Number/Well AP Sp Ac
x 10" umol AP/min mg Protein umol/min/mg
0 4.100 + 0.945 .064 + .0099 .057 + .0050 1.172 + .1294
5 4.544 + 0.558 .068 + .0081 .053 + .0089 1.386 + .2964
1.0 5.021 + 0.817 .063 + .0069 .048 + .0108" 1.445 + .4762
1.5 4.649 + 1.056 .057 + .0115 .052 + .0077 1.125 + .1570
All values are the mean +SD.
VIP was added for 70 hours in 2% serum medium.
*Significant difference at P(.05 when compared
controls.
untreated
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Experiment #3, AP Specific Activity, Cell Number and Protein Content.
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DISCUSSION
This study shows that VlP and NGF has a direct effect on
osteoblasts in culture. Even though differentiation is coupled to
growth arrest, the arrest of growth does not necessarily result in
diffeFentiation. Therefore, when studying the effect of NGF and/or
VIP on ROS 7/2.8 cells both growth (cell number) and
differentiation (AP Sp Ac) were investigated. However, under the
conditions of experiment #I, the effect was small, when compared to
the untreated control using the T-test.
The effect of VIP was more pronounced in the presence of IBMX
and NGF, which antagonize it. This is apparent when the 3-way ANOVA
was calculated; not only was there an effect of the VIP, NGF and
IBMX alone, but also an interaction (axb) on the AP Sp Ac, cell
number and protein content.
Experiment #I indicates that the addition of the
phosphodiesterase inhibitor, IBMX, either alone or in combination
with other agents tends to cause a decrease in specific activity of
alkaline phosphatase. These results following the addition of IBMX
agree with previous findings in the laboratory (Maeska and Rodan,
1982b).
Experiment #2 was designed to increase the experimental time
period from the 60 hours in experiment #I to 96 hours in experiment
#2, to investigate further the effect of the agent on cell growth.
Another important alteration in experiment #2 design was a decrease
in the concentration of serum to 0.2 FBS to reduce its effects when
examining the influence of VIP and NGF on the growth and maturation
of ROS 17/2.8 cells. This is important because the presence of
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serum adds a complicating factor because serum binds and contains
many gowth and maturation factors. Of course, a seum fee medium
would eliminate the complicating factor of seum, but also adds a
different factor, which is the difficulty for cell gFowth and
maintenance.
Other relevant changes in experiment #2, aFe that VIP was given
in one dose, the NGF conoentFation was increased and there was a
control on every plate. However, experiment #2 was inconclusive;
the difference in control values may be due to the relatively small
sample size and large SD.
Therefore, Experiment #3 was designed to increase the sample
size and to investigate vaFious concentrations of VIP. The
experimental design of experiment #5 was similar to Experiment #
with respect to serum concentration and plating density. The
results of experiment #5 suppoFt the Fesults of experiment #I:
addition of VIP in the same concentration Fange (0.5-.0 ug VIP/ml),
increased AP Sp Ao, oel.l number, and decFeased the protein content.
At the highest concentration tested (1.5 ug VIP/ml) the effect was
reduced.
The biological effect was unexpected. The effects in the
presence of IBMX appear to be the opposite of what one might expect.
Previous studies showed that PTH and isoproterenol ,increase cAMP and
decrease AP in ROS 17/2 cells. Since VIP increased cAMP in bone and
human osteosarcoma cells, one might expect an inhibition of AP in
R0S 17/2.8 cells. Since VIP antagonized the IBMX inhibitory effect
on AP, its action may not have a simple relationship to changes in
cAMP levels. In this studyVlP increased the AP Sp Ac. Also,
Hohmann and Tashjian (1984) reported that VIP increased-cAMP in the
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human osteosarooma cells. Hohmann and TashOian (198) have
routinely used IBMX and found that IBMX stimulated cAMP. Vasoactive
intestinal peptide and IBMX enhanced the production of cAMP; and
IBMX potentiated the resoptive response to low concentrations of
VIP.
In this study, the effects of VIP and NGF were found to be
small, suggesting that the ROS cells are low in receptors for these
agents. This may be a property specific
Grigoriadis et al. (1985) reported on the
to the ROS 17/2.8 clone.
subclone heterogeneity of
the ROS cells. Analysis of mixed osteoblastic cell populations or
other cloned osteoblastio lines may yield greater responses. In
that case, selection of cells on the basis of response and/or number
of receptors for VIP and/or NGF, may be useful to study the direct
effect of V IP and NGF on osteoblasts.
Two postulated general roles of the nervous system in
mechanically induced tissue remodeling are: I) The stimulated nerves
could dilate capillaries at compression sites, leading to rapid
release of inflammatory cells that actively participate in the
invasion of the hyalinized zones. 2) A direct effect of a
neurotrophic substance, such as VIP which is secreted from the
nerve, causes a response in the osteoblast. The results reported in
this study are consistent with this hypothesis. Also, Hohmann and
Tash$ian’s (1984) findings of functional receptors for VIP on human
osteosarcoma cells (SaOs-2), and the finding that VIP stimulates
bone resorption (Hohmann et al., 1983); which further supports the
proposed interaction of osteoblasts and osteoclasts (Rodan and
Martin, 1981).
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Summary and Conclusions
This investigation was undeFtaken to assess a direct neural
involvement in osteogenesis. Two neurotrophio factors, NGF and VIP
had the following effects on the ROS 17/2.8 cells.
I. VIP increased the AP Sp Ac and cell number, when measured
sixty hours following the initial addition of five doses of
0.165 ug/ml at 12 hour intervals. This condition decreased
the protein content. VIP had a similar effect when added
in a single dose of 0.825 ug/ml.
2. VIP increased the AP Sp Ac and cell number, and decreased
the protein content when measured seventy hours following
the addition of a single dose (0.50 ug/ml and 1.0 ug/ml).
5. NGF inhibited the AP Sp Ao and increased the cell number
and protein content when measured sixty hours following the
addition of a single dose (O.025ug/ml).
4. IBMX, either alone or in combination with other agents
decreased AP Sp Ac.
5. The effect of VIP in increasing AP Sp Ao was moe
pFonounoed in the pFesence of IBMX and NGF.
These results aFe consistent with the hypothesis that the
osteoblast responds directly to the neurotrophic substances VIP and
NGF.
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